Pharvaris N.V.
Pharvaris (PHVS) reported that its Phase 3 study of deucrictibant XR for hereditary angioedema (HAE) met all endpoints, reducing attack rates by 83%. The company plans to file for FDA approval in H1 2027. PHVS stock closed at $31.12, up 0.58% in after-hours trading.
Pharvaris (PHVS) announced positive results from the RAPIDe-3 study of deucrictibant IR for treating HAE attacks, published in The Lancet. The treatment showed rapid symptom relief and resolution, with a well-tolerated safety profile. The company's NDA and MAA for deucrictibant IR are under regulatory review, with a PDUFA target date of April 23, 2027.
H.C. Wainwright reiterated a Buy rating and $60 price target on Pharvaris (PHVS) due to positive Phase 3 data for deucrictibant, showing an 83% reduction in HAE attacks. The firm sees potential in treating acquired angioedema and expects FDA approval by April 2027. PHVS shares are down 19% since September 2026, trading at $30.49 with a $2.14B market cap. Analysts project significant upside, with price targets ranging from $41 to $79.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning PHVS (Pharvaris N.V.). Coverage has skewed bullish: 6 bullish, 0 neutral, and 0 bearish.
Recent PHVS coverage spans insider activity, financial news and earnings.
In the last 30 days, PHVS insiders filed 15 SEC Form 4 transactions — no purchases and 15 sales ($18.3M). The most active reporter was Glassman Robert with 2 filings. 40% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive Phase 3 data reduces clinical risk and sets up a near‑term regulatory filing.
Positive pivotal Phase 3 readout increases probability of NDA/MAA approval for deucrictibant IR and supports risk-on positioning into FDA review.
Positive Phase 3 results and upgraded analyst targets are likely to drive buying pressure.
The study highlights a market opportunity for Pharvaris' oral bradykinin antagonist, likely supporting the stock modestly.
The insider sale modestly reduces insider ownership but is unlikely to move the stock significantly.
AlphAI scores every news story that mentions PHVS with an AI model for sentiment and relevance, and aggregates insider trades from Pharvaris N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pharvaris (PHVS) reported that its Phase 3 study of deucrictibant XR for hereditary angioedema (HAE) met all endpoints, reducing attack rates by 83%. The company plans to file for FDA approval in H1 2027. PHVS stock closed at $31.12, up 0.58% in after-hours trading.
3 min readPharvaris (PHVS) announced positive results from the RAPIDe-3 study of deucrictibant IR for treating HAE attacks, published in The Lancet. The treatment showed rapid symptom relief and resolution, with a well-tolerated safety profile. The company's NDA and MAA for deucrictibant IR are under regulatory review, with a PDUFA target date of April 23, 2027.
5 min readH.C. Wainwright reiterated a Buy rating and $60 price target on Pharvaris (PHVS) due to positive Phase 3 data for deucrictibant, showing an 83% reduction in HAE attacks. The firm sees potential in treating acquired angioedema and expects FDA approval by April 2027. PHVS shares are down 19% since September 2026, trading at $30.49 with a $2.14B market cap. Analysts project significant upside, with price targets ranging from $41 to $79.
2 min readPharvaris (PHVS) published a study in Advances in Therapy showing HAE patients prefer oral prophylaxis over injections due to convenience. The analysis, based on data from 1,131 patients, found treatment satisfaction was influenced by portability, administration route, and efficacy. PHVS is developing oral bradykinin B2 receptor antagonists for HAE. The stock closed at $31.19 on October 2, 2026.
2 min readMonges Viviane sold 11,969 shares of Pharvaris N.V. (PHVS) at $33.05 ($0.40M total) on 2026-09-23.
1 min readNassif David W. (CFO / CLO) sold 6,000 shares of Pharvaris N.V. (PHVS) at $36.47 ($0.22M total) on 2026-09-21.
1 min readLu Peng (President) sold 100,000 shares of Pharvaris N.V. (PHVS) at $35.00 ($3.50M total) on 2026-09-17.
1 min readSchikan Johannes Gerardus Christiaan Petrus sold 200,000 shares of Pharvaris N.V. (PHVS) at $35.00 ($7.00M total) on 2026-09-17.
1 min readBjork Elisabeth sold 52,500 shares of Pharvaris N.V. (PHVS) at $37.89 ($1.99M total) on 2026-09-17.
1 min readGlassman Robert sold 14,493 shares of Pharvaris N.V. (PHVS) at $38.56 ($0.56M total) on 2026-09-17 under a Rule 10b5-1 trading plan.
1 min read